BACKGROUND: Following lung transplantation, prompt diagnosis and therapy of acute pulmonary rejection and infection episodes relies primarily upon changes in pulmonary function and determines long-term outcome. We tested a new system that allows daily monitoring of the patient's pulmonary status even after discharge from the hospital. METHODS: Seven lung transplant recipients from our center were equipped with a telemetric monitoring device consisting of a portable flowmeter and a special modem unit. The flowmeter measures forced vital capacity (FVC), forced expiratory volume per second (FEV1), and mid expiratory flows (MEFs), encodes information like fever, cough, and dyspnea in a binary code form, and stores all values in a 32 kB memory unit. After its use, the patient positions the flowmeter onto the modem unit which automatically connects to a central computer at our center to transfer all saved data. The whole set can be used via any regular phone jack. The patient's file in the computer can be checked every day. RESULTS: All patients learned to use the unit during their postoperative stay or during later follow-up, and were able to apply the system at home. In a mean follow-up period of 10.3+/-2.2 months, 15 episodes of significant deterioration in home pulmonary function tests (PFTs) (>10%) were registered in 6 patients, which were all confirmed by in-hospital body plethysmography. They resulted in diagnoses of 4 episodes of acute rejection, 6 cases of beginning bacterial pneumonia, and 5 cases of, most likely, viral tracheobronchitis. Only 1 patient had to be admitted to the hospital. All patients PFTs returned to previous values after treatment. CONCLUSIONS: Telemetric monitoring of graft function in lung transplant recipients allows reliable early diagnosis and treatment of infection or rejection, which might help to prevent exacerbation of the pathology and reduce quantity of amounting graft dysfunction.
BACKGROUND: Following lung transplantation, prompt diagnosis and therapy of acute pulmonary rejection and infection episodes relies primarily upon changes in pulmonary function and determines long-term outcome. We tested a new system that allows daily monitoring of the patient's pulmonary status even after discharge from the hospital. METHODS: Seven lung transplant recipients from our center were equipped with a telemetric monitoring device consisting of a portable flowmeter and a special modem unit. The flowmeter measures forced vital capacity (FVC), forced expiratory volume per second (FEV1), and mid expiratory flows (MEFs), encodes information like fever, cough, and dyspnea in a binary code form, and stores all values in a 32 kB memory unit. After its use, the patient positions the flowmeter onto the modem unit which automatically connects to a central computer at our center to transfer all saved data. The whole set can be used via any regular phone jack. The patient's file in the computer can be checked every day. RESULTS: All patients learned to use the unit during their postoperative stay or during later follow-up, and were able to apply the system at home. In a mean follow-up period of 10.3+/-2.2 months, 15 episodes of significant deterioration in home pulmonary function tests (PFTs) (>10%) were registered in 6 patients, which were all confirmed by in-hospital body plethysmography. They resulted in diagnoses of 4 episodes of acute rejection, 6 cases of beginning bacterial pneumonia, and 5 cases of, most likely, viral tracheobronchitis. Only 1 patient had to be admitted to the hospital. All patients PFTs returned to previous values after treatment. CONCLUSIONS: Telemetric monitoring of graft function in lung transplant recipients allows reliable early diagnosis and treatment of infection or rejection, which might help to prevent exacerbation of the pathology and reduce quantity of amounting graft dysfunction.
Authors: Hojung J Yoon; Hojung Joseph Yoon; Hongfei Guo; Marshall Hertz; Marshall I Hertz; Stanley Finkelstein; Stanley M Finkelstein Journal: AMIA Annu Symp Proc Date: 2008-11-06
Authors: N Lechtzin; N West; S Allgood; E Wilhelm; U Khan; N Mayer-Hamblett; M L Aitken; B W Ramsey; M P Boyle; P J Mogayzel; C H Goss Journal: Contemp Clin Trials Date: 2013-09-19 Impact factor: 2.226
Authors: Yun Jiang; Susan M Sereika; Annette DeVito Dabbs; Steven M Handler; Elizabeth A Schlenk Journal: Int J Med Inform Date: 2016-07-19 Impact factor: 4.046
Authors: Stanley M Finkelstein; Bruce R Lindgren; William Robiner; Ruth Lindquist; Marshall Hertz; Bradley P Carlin; Arin VanWormer Journal: Telemed J E Health Date: 2013-10-01 Impact factor: 3.536
Authors: Chadi A Hage; Julia Klesney-Tait; Keith Wille; Selim Arcasoy; Gordon Yung; Marshall Hertz; Kevin M Chan; Matt Morrell; Hilary Goldberg; Suresh Vedantham; Mary Clare Derfler; Paul Commean; Keith Berman; Ed Spitznagel; Jeff Atkinson; George Despotis Journal: Transfus Med Date: 2021-05-05 Impact factor: 2.019